Franklin Parlapiano Turner & Welch LLC cut its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,649 shares of the medical instruments supplier’s stock after selling 437 shares during the period. Becton Dickinson and accounts for about 2.6% of Franklin Parlapiano Turner & Welch LLC’s holdings, making the stock its 10th biggest position. Franklin Parlapiano Turner & Welch LLC’s holdings in Becton Dickinson and were worth $6,433,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in BDX. Acropolis Investment Management LLC purchased a new position in Becton Dickinson and in the 3rd quarter valued at $101,000. Almanack Investment Partners LLC. purchased a new position in Becton Dickinson and in the 2nd quarter valued at $105,000. Truvestments Capital LLC purchased a new position in Becton Dickinson and in the 3rd quarter valued at $105,000. Bartlett & Co. LLC grew its position in Becton Dickinson and by 2,900.0% in the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after buying an additional 435 shares during the last quarter. Finally, Bridgeworth LLC purchased a new position in Becton Dickinson and in the 2nd quarter valued at $131,000. Institutional investors and hedge funds own 92.57% of the company’s stock.
Becton Dickinson and stock opened at $235.58 on Friday. Becton Dickinson and Co has a one year low of $209.91 and a one year high of $265.87. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. The firm has a market capitalization of $63.03 billion, a price-to-earnings ratio of 24.85, a price-to-earnings-growth ratio of 1.40 and a beta of 1.19.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The company had revenue of $4.28 billion during the quarter, compared to the consensus estimate of $4.25 billion. During the same quarter last year, the company earned $2.46 earnings per share. Becton Dickinson and’s quarterly revenue was up 41.0% compared to the same quarter last year. On average, analysts predict that Becton Dickinson and Co will post 11.01 earnings per share for the current year.
A number of equities analysts recently weighed in on BDX shares. KeyCorp reiterated a “buy” rating and issued a $264.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. Royal Bank of Canada reiterated a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. Citigroup lifted their price objective on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Wells Fargo & Co lifted their price objective on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research report on Thursday, September 6th. They noted that the move was a valuation call. Finally, Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research report on Thursday, October 4th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $256.14.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.